drugset
Drugs / OLCEGEPANT
last change Feb 2004 re-read 3 minutes ago

OLCEGEPANT

also known as BIBN 4096 BS · SD I · SD II

Small molecule targets CALCRL via inhibition

Developed for
migraine disorder
Investigated by
Boehringer Ingelheim

Trials 7

today NCT02199860 · Ph 1 NCT02194322 · Ph 1 NCT02194777 · Ph 1 NCT02194335 · Ph 1 NCT02198326 · Ph 1 NCT02198339 · Ph 2 NCT02198352 · Ph 1
199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 16 trials
Phase 1 NCT02199860 May 2003 → Feb 2004 — Boehringer Ingelheim Completed No outcome recorded
Phase 1 NCT02194322 Nov 2001 → Jan 2002 — Boehringer Ingelheim Completed No outcome recorded
Phase 1 NCT02194777 Jun → Aug 2001 — Boehringer Ingelheim Completed No outcome recorded
Phase 1 NCT02194335 Oct → Dec 2000 — Boehringer Ingelheim Completed No outcome recorded
Phase 1 NCT02198326 Jul → Aug 1999 — Boehringer Ingelheim Completed No outcome recorded
Phase 1 NCT02198352 Jun → Aug 1998 — Boehringer Ingelheim Completed No outcome recorded
Phase 21 trial
Phase 2 NCT02198339 Feb → Dec 1999 migraine disorder Boehringer Ingelheim Completed No outcome recorded

Evidence & citations 8 cited values

Every value below carries the sentence it was read from. 8 sources stand behind the page.

FieldValueCited text
Known as OLCEGEPANT ChEMBL registry synonym — accepted as the source's own label CHEMBL207197 ↗
Known as BIBN 4096 BS “The purpose of the present study was to obtain information about the safety, tolerability and pharmacokinetics of BIBN 4096 BS after single inhalation administration of rising...” NCT02199860 ↗
6

NCT02198339 ↗

NCT02194335 ↗

NCT02198352 ↗

NCT02194322 ↗

NCT02198326 ↗

NCT02194777 ↗
Known as SD I “According to the original protocol, the primary objective was to investigate the safety and tolerability of single doses of a new spray-dried inhalation formulation of BIBN...” NCT02199860 ↗
Known as SD II “The purpose of the present study was to obtain information about the safety, tolerability and pharmacokinetics of BIBN 4096 BS after single inhalation administration of rising...” NCT02199860 ↗
Action Inhibit “Calcitonin gene-related peptide type 1 receptor antagonist” CHEMBL207197 ↗
Modality Small molecule — CHEMBL207197 ↗
Route Intranasal “After Intranasal Administration” NCT02194322 ↗
Target CALCRL “Calcitonin gene-related peptide type 1 receptor antagonist” CHEMBL207197 ↗